» Articles » PMID: 1379568

Surface Epithelium Related Activation of Complement Differs in Crohn's Disease and Ulcerative Colitis

Overview
Journal Gut
Specialty Gastroenterology
Date 1992 Jul 1
PMID 1379568
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

IgG1 and activated complement are colocalised on the colonic epithelial brush border in active ulcerative colitis. To investigate whether such deposition is specific for ulcerative colitis, we examined ethanol fixed mucosal specimens from 18 patients with Crohn's colitis and 14 with terminal ileitis by indirect two colour immunofluorescence staining. Monoclonal antibodies to the IgG subclasses and to neoepitopes of activated complement C3b and the terminal complement complex were used in combination with rabbit antiserum to C1q, C4c or cytokeratin. Granular deposition of C3b and terminal complement complex were observed at the luminal face of the surface epithelium in 10 of 18 patients with Crohn's colitis. Specimens from eight of 14 patients with ileal involvement were intensely stained for activated complement (primarily C3b) within the surface mucus layer. No epithelial IgG, C1q or C4c deposition was observed. The results suggest that early and late phase complement activation takes place at the luminal face of the epithelium in Crohn's disease. The absence of colocalised IgG and complement components involved in the classical activation pathway (C1q and C4c), however, suggest that other immunopathological mechanisms (the alternative pathway?) are primarily involved in Crohn's disease in contrast with ulcerative colitis.

Citing Articles

Complement C3-Deficiency-Induced Constipation in FVB/N-C3/Korl Knockout Mice Was Significantly Relieved by Uridine and L. Extracts.

Song H, Kim J, Jin Y, Roh Y, Seol A, Kim T Int J Mol Sci. 2023; 24(21).

PMID: 37958740 PMC: 10649790. DOI: 10.3390/ijms242115757.


IgA nephropathy associated with Crohn's disease.

Tamura H World J Methodol. 2023; 13(3):67-78.

PMID: 37456980 PMC: 10348078. DOI: 10.5662/wjm.v13.i3.67.


A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement.

Mehta R, Ali H, Dai Y, Yao B, Overman B, Ratanatharathorn V Bone Marrow Transplant. 2023; 58(9):991-999.

PMID: 37202544 PMC: 10195122. DOI: 10.1038/s41409-023-01996-4.


Helicobacter pylori initiates successful gastric colonization by utilizing L-lactate to promote complement resistance.

Hu S, Ottemann K Nat Commun. 2023; 14(1):1695.

PMID: 36973281 PMC: 10042806. DOI: 10.1038/s41467-023-37160-1.


The neoepitope of the complement C5b-9 Membrane Attack Complex is formed by proximity of adjacent ancillary regions of C9.

Bayly-Jones C, Ho B, Lau C, Leung E, DAndrea L, Lupton C Commun Biol. 2023; 6(1):42.

PMID: 36639734 PMC: 9838529. DOI: 10.1038/s42003-023-04431-y.


References
1.
Claus D, Siegel J, Petras K, Osmand A, Gewurz H . Interactions of C-reactive protein with the first component of human complement. J Immunol. 1977; 119(1):187-92. View

2.
Bagchi S, Das K . Detection and partial characterization of Crohn's disease tissue specific proteins recognized by Crohn's disease sera. Clin Exp Immunol. 1984; 55(1):41-8. PMC: 1535791. View

3.
Baklien K, Brandtzaeg P . Comparative mapping of the local distribution of immunoglobulin-containing cells in ulcerative colitis and Crohn's disease of the colon. Clin Exp Immunol. 1975; 22(2):197-209. PMC: 1538296. View

4.
Halstensen T, Mollnes T, Garred P, Fausa O, Brandtzaeg P . Epithelial deposition of immunoglobulin G1 and activated complement (C3b and terminal complement complex) in ulcerative colitis. Gastroenterology. 1990; 98(5 Pt 1):1264-71. DOI: 10.1016/0016-5085(90)90343-y. View

5.
Ahrenstedt O, Knutson L, Nilsson B, Nilsson-Ekdahl K, Odlind B, Hallgren R . Enhanced local production of complement components in the small intestines of patients with Crohn's disease. N Engl J Med. 1990; 322(19):1345-9. DOI: 10.1056/NEJM199005103221903. View